HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pseudomonas Infections

Infections with bacteria of the genus PSEUDOMONAS.
Also Known As:
Infections, Pseudomonas; Pseudomonas aeruginosa Infection; Infection, Pseudomonas; Pseudomonas Infection; Pseudomonas aeruginosa Infections
Networked: 1913 relevant articles (128 outcomes, 140 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Cystic Fibrosis (Mucoviscidosis)
2. Infections
3. Burns
4. Wounds and Injuries (Trauma)
5. Sepsis (Septicemia)

Experts

1. Oliver, Antonio: 15 articles (01/2022 - 05/2006)
2. Ratjen, Felix: 12 articles (10/2020 - 03/2007)
3. Gulbins, Erich: 10 articles (01/2021 - 04/2008)
4. Wu, Min: 9 articles (01/2021 - 02/2008)
5. Mayer-Hamblett, Nicole: 8 articles (01/2022 - 06/2007)
6. Waters, Valerie: 8 articles (01/2022 - 11/2012)
7. Ramsey, Bonnie W: 7 articles (01/2022 - 10/2003)
8. Gibson, Ronald L: 7 articles (11/2021 - 10/2003)
9. Elborn, J Stuart: 7 articles (01/2021 - 02/2007)
10. Behrouz, Bahador: 7 articles (01/2020 - 09/2015)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Pseudomonas Infections:
1. Anti-Bacterial Agents (Antibiotics)IBA
2. Tobramycin (Nebcin)FDA LinkGeneric
3. AminoglycosidesIBA
4. Gentamicins (Gentamicin)FDA LinkGeneric
5. ExotoxinsIBA
6. beta-LactamsIBA
7. Ciprofloxacin (Cipro)FDA LinkGeneric
8. Colistin (Coly-Mycin)FDA Link
9. Monoclonal AntibodiesIBA
10. QuinolonesIBA

Therapies and Procedures

1. Therapeutics
2. Phage Therapy
3. Punctures
4. Length of Stay
01/01/2022 - "Secondary outcomes were Length of Stay (LOS), Secondary Bacterial Infections (SBI), and MRSA (Methicillin-Resistant Staphylococcus aureus), and Pseudomonas infections. "
03/07/2017 - "When compared to Group1, patients in Group 2 were 5 years older (p = 0.009), more likely to have diabetes mellitus (61 vs 41%, p < 0.001), Pseudomonas aeruginosa infection (p = 0.004), greater Sequential Organ Failure Assessment (SOFA) score (11.5 ± 3 vs 8 ± 2, p = 0.001), and prolonged intensive care (median 7 vs 5 days) and hospital length of stay (22 vs 11 days, p = 0.001). "
08/15/2011 - "In one published study comparing the use of EI and traditional piperacillin-tazobactam infusion schemes in critically ill patients with Pseudomonas aeruginosa infection, EI therapy was associated with significantly improved 14-day mortality and significantly shorter hospital stays; a few other studies have yielded less favorable results. "
11/01/2014 - "Variables of interest included age, gender, presence of solid tumor or hematologic disease, cancer status, central venous catheter use, previous Pseudomonas aeruginosa infection, infection by multidrug resistant-Gram-negative bacteria, colonization by multidrug resistant-Gram-negative bacteria, neutropenia in the preceding seven days, neutropenia duration ≥3 days, healthcare-associated infection, length of stay before intensive care unit admission, length of intensive care unit stay >3 days, appropriate empirical antimicrobial treatment, definitive inadequate antimicrobial treatment, time to initiate adequate antibiotic therapy, appropriate antibiotic duration ≤3 days, and shock. "
09/01/2015 - "Variables of interest included age, gender, presence of solid tumor or hematologic disease, cancer status, central venous catheter use, previous Pseudomonas aeruginosa infection, healthcare-associated infection, neutropenia in the preceding 7 days, duration of neutropenia, length of hospital stay before ICU admission, length of ICU stay, and the use of any of the following in the previous 30 days: antimicrobial agents, corticosteroids, chemotherapy, or radiation therapy. "
5. Stents